- In February 2025, The U.S. FDA approved EMBLAVEO (aztreonam and avibactam), the first monobactam/β-lactamase inhibitor combination, to treat complicated intra-abdominal infections (cIAI) in adults with limited treatment options. It targets Gram-negative bacteria, including resistant strains. This approval addresses growing antimicrobial resistance, a significant North America health threat
- In February 2024, Johnson & Johnson, along with its partner Pharmacyclics LLC (an AbbVie Company), has received FDA approval for an expanded label for IMBRUVICA (ibrutinib) in an oral suspension form. This expansion allows for the treatment of adult patients with CLL/SLL, WM, and cGVHD after prior systemic therapy
- In March 2024, Johnson & Johnson has announced the successful completion of its acquisition of Ambrx Biopharma, Inc. This clinical-stage biopharmaceutical company possesses a proprietary synthetic biology technology platform used for designing and developing next-generation antibody drug conjugates (ADCs). This acquisition offers Johnson & Johnson a unique opportunity to create, develop, and market targeted oncology therapies
- In February 2024, AbbVie Inc. and Tentarix Biotherapeutics have announced a partnership to collaboratively discover and develop conditionally-active, multi-specific biologics in the fields of oncology and immunology. This collaboration will leverage AbbVie's extensive experience in these areas alongside Tentarix's proprietary Tentacles platform
- In September 2021, Sanofi has finalized a merger agreement with Kadmon Holdings, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases with substantial unmet medical needs. This acquisition aligns with Sanofi's growth strategy for its General Medicines core assets and will promptly incorporate Rezurock (belumosudil) into its transplant portfolio
